Anjan Aralihalli | President & Founder
Raya Therapeutic, Inc.

Anjan founded Raya Therapeutic in 2019. Raya is focused on developing multiple drugs to treat ALS and potentially other neurodegenerative diseases. Raya is currently focused on starting a robust P2 trial across multiple clinical centres in the UK in the fall of 2026. In addition, the company plans to start multiple trials in 2027 in ALS as well as an ultra-rare pediatric neurodegenerative disease. If the pediatric program ultimately gets approved by the FDA, it would lead to the receipt of a Pediatric Priority Review Voucher. The last 8 vouchers sold in 2026 had a value of $180-220M USD. Prior to Raya, Anjan worked at a variety of biotechs and pharma companies and is a venture partner at CTI Life Sciences Fund 2 (Canada). He has 25+ years of international experience across several functions including investor relations, corporate development, venture and angel financing, in & out-licensing, sales, marketing, & clinical trial management. He continues to provide strategic advice to various biotech companies. Based in the Princeton, New Jersey area, Anjan was also previously a member of a NYC based angel investment group called Mid-Atlantic Bio Angels (MABA). He received his BSc from Concordia University, MBA from Queen's University and MSc in Biotechnology from Johns Hopkins University. Anjan is a corporate fundraiser for Wings Over Wall Street, a NYC based ALS charity and is a member of the board of directors of the Muscular Dystrophy Association (MDA) in the United States.